The authors identified 157 lesions among 114 patients that met inclusion criteria from 2014-2017 who underwent mpMRI and targeted biopsy. To characterize lesion heterogeneity, only men with ≥2 positive targeted biopsy cores were included in the study. Histologic grades were scored according to International Society of Urological Pathology (ISUP) grades. Lesion heterogeneity was reported as a heterogeneity index (HI) and calculated as the difference of the average ISUP grades of targeted biopsy cores per lesion from the maximum sampled ISUP grade of that lesion. Maximum ISUP grade ranged from 1 to 5, with a median ISUP grade of 2. Higher ISUP grades were associated with greater lesion heterogeneity (HI for ISUP grade ≥3 = 0.58 ± 0.11 vs <3 = 0.29 ± 0.08, p = 0.0001). Second, increasing lesion size on mpMRI was associated with greater lesion heterogeneity (HI for ≥2cm = 0.52 ± 0.14 vs <2cm = 0.32 ± 0.08, p = 0.0096). Finally, higher mpMRI suspicion scores were associated with increased heterogeneity vs lower suspicion scores (0.46 ± 0.48 vs 0.31 ± 0.35; p = 0.033).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Presented by: Samuel Gold, National Cancer Institute, Bethesda, MD
Co-Authors: Jonathan Bloom, Graham R. Hale, Kareem Rayn, Sherif Mehralivand, Brad J. Wood, Baris Turkbey, Peter A. Pinto
Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA